<DOC>
	<DOCNO>NCT01223235</DOCNO>
	<brief_summary>The immune system body ability fight eliminate infection cancer . Immune treatment , study , seek teach immune system find destroy cancer cell . The purpose study test whether safe treat cancer vaccine another drug call bevacizumab ( also know Avastin ) .</brief_summary>
	<brief_title>Polyvalent Vaccine-KLH Conjugate + Opt-821 Given Combination With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically document epithelial carcinoma arise ovary , fallopian tube peritoneum . Patients receive cytoreductive surgery chemotherapy least one platinum base chemotherapy regimen . Patients receive neoadjuvant chemotherapy eligible . Patients relapse ovarian , fallopian tube primary peritoneal cancer complete chemotherapy and/or surgery recurrent disease . Eligible patient would appropriate enter period observation standard management consider . Patients asymptomatic residual measurable disease CT scan complete clinical remission . Patients may elevate CA125 . ( Complete clinical remission define serum CA125 ≤ 35 IU/ml , negative physical examination without objective evidence disease compute tomography ( CT ) abdomen pelvis . ) Adequate hematologic , coagulation , renal hepatic function . ANC &gt; = 1,000 cells/mm3 ; platelet &gt; = 100,000 cells/mm3 PT international normalize ratio ( INR ) &lt; 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) Serum creatinine &lt; = 1.5 mg/dl Bilirubin , SGOT , Alk Phos &lt; 2.5x upper limit normal Urine protein : creatinine ( UPC ) ratio must &lt; 1 . If UPC ratio &gt; 1 , collection 24hour urine measurement urine protein recommend part patient 's medical management offstudy . Karnofsky performance status &gt; 70 % Expected survival least 4 month Age ≥ 18 year . This protocol include child number child cancer limit , nationwide pediatric cancer research network already access majority . Furthermore , incidence ovarian , fallopian tube , peritoneal cancer child extremely infrequent . Patients ≥ 4 week completion prior cytotoxic chemotherapy . Prior bevacizumab and/or immunotherapy treatment permit Inability comply study and/or followup procedure Current recent ( within 4 week first infusion study ) participation another experimental drug study . Active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last five year Patients must undergo standard cytoreductive surgery part primary treatment eligible study therefore childbearing potential.Nursing mother exclude . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix C ) History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Known CNS disease , except treat brain metastasis Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) tumor involve major vessel . Major surgical procedure laparotomy , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day Patients clinical symptom sign GI obstruction require parenteral hydration , parenteral nutrition , tube feeding Patients evidence abdominal free air explain paracentesis recent surgical procedure Serious , nonhealing wound , active ulcer , untreated bone fracture Known hypersensitivity component bevacizumab Allergy seafood Active autoimmune disease ( i.e . rheumatoid arthritis , ulcerative colitis etc ) ; immune deficiency ( HIV , hypogammaglobulinemia ) ; know active infection Hepatitis B Hepatitis C ; receive immunosuppressive drug ( chronic systemic corticosteroid cyclosporin , etc ) ; receive chronic antiinflammatory drug ( intermittent use antiinflammatory drug permit ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>FALLOPIAN TUBE</keyword>
	<keyword>OVARY</keyword>
	<keyword>PERITONEUM</keyword>
	<keyword>BEVACIZUMAB ( AVASTIN )</keyword>
	<keyword>GLOBO H-KLH CONJUGATE</keyword>
	<keyword>MUC-1 KLH</keyword>
	<keyword>OPT-821</keyword>
	<keyword>TF ( C ) - KLH</keyword>
	<keyword>TN ( C ) -KLH</keyword>
	<keyword>10-099</keyword>
</DOC>